Indeed, PD-L1 expression is observed in various cancers including lung, melanoma, breast, kidney cancer, and Hodgkin lymphoma, and it is widely accepted as key biomarker for predicting clinical response to anti–PD-1/PD-L1 therapy [5, 18, 19]. The gene discussed is CD274; the disease is kidney cancer.